title: Clinicopathologic study and outcome analysis of thyroid lymphomas: experience from a tertiary cancer center.
abstract: BACKGROUND
  The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.
  
  
  METHODS
  The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl-6) and activated B-cell immunophenotype markers (FoxP1, Mum1).
  
  
  RESULTS
  During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B-cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.
  
  
  CONCLUSIONS
  Advanced International Prognostic Index (IPI) score and combined-modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B-cell lymphoma as elsewhere.
authors.affiliation: Department of Head and Neck Surgery, Tata Memorial Centre, Mumbai, India.
authors.forename: Rakesh
authors.initials: R
authors.lastname: Katna
authors.forename: Tanuja
authors.initials: T
authors.lastname: Shet
authors.forename: Manju
authors.initials: M
authors.lastname: Sengar
authors.forename: Hari
authors.initials: H
authors.lastname: Menon
authors.forename: Siddharth
authors.initials: S
authors.lastname: Laskar
authors.forename: Kumar
authors.initials: K
authors.lastname: Prabhash
authors.forename: Anil
authors.initials: A
authors.lastname: D'Cruz
authors.forename: Reena
authors.initials: R
authors.lastname: Nair
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D044963:Biopsy, Fine-Needle; D059248:Chemoradiotherapy / Q000379:methods; D016208:Databases, Factual; D018572:Disease-Free Survival; D005260:Female; D051858:Forkhead Transcription Factors / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012097:Repressor Proteins / Q000235:genetics*; D012189:Retrospective Studies; D018570:Risk Assessment; D012737:Sex Factors; D016019:Survival Analysis; D062606:Tertiary Care Centers; D013964:Thyroid Neoplasms / Q000235:genetics / Q000401:mortality / Q000473:pathology* / Q000628:therapy*
chemical_list: C486626:FOXP1 protein, human; D051858:Forkhead Transcription Factors; D012097:Repressor Proteins